Regeneron’s Cemiplimab Study: Real-World Insights and Market Impact

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Study Overview: The Cemiplimab Survivorship Epidemiology (CASE) Study, conducted by Regeneron Pharmaceuticals, aims to evaluate the effectiveness and safety of cemiplimab in treating advanced cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) in real-world settings. The study focuses on patient outcomes, safety, and treatment patterns, providing valuable insights into the drug’s performance outside of controlled clinical trials.

Intervention/Treatment: The study examines cemiplimab, a drug administered every three weeks, intended to treat patients with advanced CSCC or BCC. The focus is on real-world application, assessing its effectiveness and safety in everyday clinical practice.

Study Design: This observational cohort study employs a prospective time perspective. It does not involve allocation or masking, as it observes the outcomes of patients already receiving cemiplimab in real-world settings. The primary purpose is to gather data on the drug’s real-world effectiveness and safety.

Study Timeline: The study began on February 7, 2019, and was completed, with the last update submitted on October 13, 2025. These dates mark the study’s progression and its recent update, indicating ongoing analysis and data collection.

Market Implications: The completion and update of this study could positively influence Regeneron’s stock performance by reinforcing cemiplimab’s market position in treating advanced CSCC and BCC. As the study provides real-world evidence of the drug’s effectiveness and safety, it may enhance investor confidence and competitiveness against other treatments in the oncology market.

The study is ongoing, with further details available on the ClinicalTrials portal.